Publications by authors named "Anthony D Elias"

Claim this Profile
N
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Anthony D Elias

J Natl Compr Canc Netw· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.
Breelyn A Wilky, Katherine A Julian, Alessandra Maleddu, Anne C Mailhot, Chelsey R Cartwright, Anthony D Elias

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report.
Alessandra Maleddu, Trista K Hinz, Margaret A Black, Dara L Aisner, Carrie B Marshall, Anthony D Elias

JTO Clin Res Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.
Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer, Anthony D Elias

J Immunother Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Anthony D Elias

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Anthony D Elias

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.
Anthony D Elias, Alyse W Staley, Monica Fornier, Gregory A Vidal, Vida Alami

NPJ Breast Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Anthony D Elias

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, Anthony D Elias

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien, Anthony D Elias

JAMA Netw Open· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Anthony D Elias

J Natl Compr Canc Netw· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Anthony D Elias, Nicole S Spoelstra, Alyse W Staley, Sharon Sams, Lyndsey S Crump

NPJ Breast Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring Amplification.
Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A Previs, Anthony D Elias

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, Anthony D Elias

NPJ Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem, Anthony D Elias

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Anthony D Elias

J Natl Compr Canc Netw· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Sant P Chawla, Brian A Van Tine, Seth M Pollack, Kristen N Ganjoo, Anthony D Elias

J Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
W Fraser Symmans, Christina Yau, Yunn-Yi Chen, Ron Balassanian, Molly E Klein, Anthony D Elias

JAMA Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Douglas Yee, Claudine Isaacs, Denise M Wolf, Christina Yau, Paul Haluska, Anthony D Elias

NPJ Breast Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, Victoria S Blinder, Jared C Foster, Anthony D Elias

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Lajos Pusztai, Christina Yau, Denise M Wolf, Hyo S Han, Lili Du, Anthony D Elias

Cancer Cell· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Anthony D Elias

J Natl Compr Canc Netw· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Neeta Somaiah, Brian Andrew Van Tine, Amy E Wahlquist, Mohammed M Milhem, Elizabeth G Hill, Anthony D Elias

Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
Heather M Brechbuhl, Kiran Vinod-Paul, Austin E Gillen, Etana G Kopin, Kari Gibney, Anthony D Elias

Mol Carcinog· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

JAMA Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis